Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
JACC: Heart Failure · 2024
DOI: 10.1016/j.jchf.2024.03.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Heart Failure, 2024. Verfasst von Neal M Dixit und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, University of California, Davis, Sacramento, California, USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Cost-Benefit Analysis, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Three medications are now guideline-recommended treatments for heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), however, the cost-effectiveness of these agents in combination has yet to be established. OBJECTIVES: The purpose of this study was to determine the cost-effectiveness of mineralocorticoid receptor antagonists (MRA), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium glucose co-transporter 2 inhibitors (SGLT2is) in individuals with HFmrEF/HFpEF. METHODS: Using a 3-state Markov model, we performed a cost-effectiveness study using simulated cohorts of 1,000 patients with HFmrEF and HFpEF. Treatment with 1-, 2-, and 3-drug combinations was modeled. Based on a United States health care sector perspective, outcome data was used to calculate incremental cost-effectiveness ratios (ICERs) in 2023 United States dollars based on a 30-year time horizon. RESULTS: Treatment with MRA, MRA+SGLT2i, and MRA+SGLT2i+ARNI therapy resulted in an increase in life years of 1.04, 1.58, and 1.80 in the HFmrEF subgroup, respectively, and 0.99, 1.54, and 1.77 in the HFpEF subgroup, respectively, compared with placebo. At a yearly cost of $18, MRA therapy resulted in ICERs of $10,000 per quality-adjusted life year (QALY) in both subgroups. The ICER for the addition of SGLT2i therapy ($4,962 per year) was $113,000 per QALY in the HFmrEF subgroup and $141,000 in the HFpEF subgroup. The addition of ARNI therapy ($5,504 per year) resulted in ICERs >$250,000 per QALY in both subgroups. If SGLT2i and ARNI were available at generic pricing the ICERs become
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, University of California, Davis, Sacramento, California, USA.
- Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA; Division of Cardiology, Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, Californ…
- Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Electronic address: gfonarow@mednet.ucla.edu.
Zitieren
APA
Dixit, N. M., Truong, K. P., Vaduganathan, M., Ziaeian, B., & Fonarow, G. C. (2024). Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2024.03.006
Vancouver
Dixit NM, Truong KP, Vaduganathan M, Ziaeian B, Fonarow GC. Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure. 2024. doi:10.1016/j.jchf.2024.03.006
BibTeX
@article{Dixit2024,
author = {Dixit, Neal M and Truong, Katie P and Vaduganathan, Muthiah and Ziaeian, Boback and Fonarow, Gregg C},
title = {Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction},
journal = {JACC: Heart Failure},
year = {2024},
doi = {10.1016/j.jchf.2024.03.006}
}
EUVIMED